問卷

TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Radiation Therapy

Division of General Surgery

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

陳彥仰
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

158Cases

2024-01-01 - 2028-12-31

Others

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2024-03-01 - 2028-10-10

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2024-03-15 - 2032-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-06-01 - 2029-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2016-06-01 - 2024-06-28

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Terminated6Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-09-01 - 2020-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Terminated5Sites

2017-08-10 - 2021-06-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Terminated12Sites

2017-09-01 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Terminated11Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2018-07-30 - 2020-09-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-10-17 - 2024-08-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Terminated4Sites